Results 221 to 230 of about 191,557 (278)

Cognitive Trajectories from Preclinical Alzheimer's Disease to Dementia

open access: yesAdvanced Science, EarlyView.
A continuous, multi‐domain characterization of cognitive decline across the Alzheimer's disease spectrum identifies when individual cognitive measures become abnormal. Episodic memory declines first, followed by executive function, language, processing speed, and visuospatial abilities, supporting improved clinical interpretation and optimized endpoint
Fredrik Öhman   +3 more
wiley   +1 more source

A Functionally Conserved Enhancer is Critical for PGC1A Expression and Thermogenesis in Brown Fat

open access: yesAdvanced Science, EarlyView.
An evolutionarily conserved enhancer controls PGC1A expression and thermogenic activation in brown adipose tissue. Integrative multi‐omics analyses identify two BAT‐specific enhancers, with PGC1A‐En1 functioning as the dominant regulatory element that maintains thermogenic capacity across species.
Duo Su   +10 more
wiley   +1 more source

<i>LL-37</i> as a biomarker for therapeutic response to scaling and root planing.

open access: yesJ Indian Soc Periodontol
Rao KS   +5 more
europepmc   +1 more source

A Radioresistant‐Tumor‐Targeted Nanoparticle for X‐Ray‐Controlled Nitric Oxide Release to Potentiate Radiotherapy

open access: yesAdvanced Science, EarlyView.
The PBTN targets GRP78 and, upon X‐ray irradiation, generates ONOO− to induce immunogenic cell death, thereby activating CD8+ T cells and establishing a systemic antitumor immune response. ABSTRACT Nitric oxide (NO) treated radioresistant tumors by relieving hypoxia and blocking DNA repair, but its nonselective toxicity has precluded therapeutic use ...
Wanze Zhang   +10 more
wiley   +1 more source

The AUTACE That Degrades KRAS and Engages CD8+ T Cells for the Treatment of KRAS/TP53 Co‐Mutant Tumors

open access: yesAdvanced Science, EarlyView.
AUTACE is a bifunctional nanoplatform that integrates tumor targeting, immune engagement, and on‐demand KRAS degradation. It targets KRAS/TP53 co‐mutant tumors via TP53‐specific TCRs, elicits antitumor CD8+ T‐cell responses through surface anti‐CD3 antibodies, and uses low‐intensity focused ultrasound (LIFU) to trigger controlled release of the KRAS ...
Luo Li   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy